MedPath

Role of microRNA in the Development of Cutaneous Squamous Cell Carcinoma

Not Applicable
Terminated
Conditions
Cancer of the Skin
Interventions
Genetic: Arm A
Registration Number
NCT01143311
Lead Sponsor
Centre Hospitalier Universitaire de Nice
Brief Summary

The aim of this study is to analyze the differential expression of the miR transcriptome in the distinctive stages of the development of cutaneous squamous cell carcinoma (C-SCC). In this aim the investigators plan to recruit a cohort of 20 patients suffering of C-SCC and to collect from each of them, biopsies corresponding to i) non UV-exposed areas ii) UV-exposed areas, iii) actinic keratosis and iv) tumoral regions. Total RNAs will be prepared from each biopsy and the miRNA profiles will be characterized using a dedicated miR array.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • patient older than 40th, suffering of a C-SCC
  • letter of consent signed by the patient
  • to be registered to social security
Exclusion Criteria
  • Pregnant women or breastfeeding.
  • Small C-SCC (size < 6mm)
  • Allergy to Xylocaine
  • All vulnerable (minor, adult guardianship...)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
ARM AArm A4 distinct biopsies will be taken 1. in a non UV-exposed area (inner arm) 2. in a UV-exposed area (external surface of the forearm) 3. in a pretumoral region (actinic keratosis) 4. inside the tumor
Primary Outcome Measures
NameTimeMethod
miRNAs1 year

We will select the miRNAs differently expressed between biopsies obtained respectively from areas of normal, pretumoral and tumoral areas (candidate miRs = miRs potentially involved in tumor transformation of epidermal keratinocytes). This will be assessed by analyzing in each of the biopsies from each patient, the expression of different miRs that are known to date, using a dedicated microarray, then by checking the data obtained by quantitative PCR.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHU de Nice - 4 avenue Reine Victoria - Hôpital de Cimiez

🇫🇷

Nice, Alpes-Maritimes, France

© Copyright 2025. All Rights Reserved by MedPath